BriaCell Announces Update On Phase 3 Clinical Progress In Pivotal Metastatic Breast Cancer Study

Benzinga · 10/15 11:56
  • 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)
  • Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician's choice
  • Interim data analysis planned at 144 events (deaths) could provide full approval and marketing authorization
  • Pivotal Phase 3 study patient enrollment completion is expected in mid-2025
  • No serious adverse events related to Bria-IMT™ have been reported to date